ClinicalTrials.Veeva

Menu

PERCI- Medium Cut Off (MCO) (PERCI-MCO)

V

Vantive Health LLC

Status

Completed

Conditions

Chronic Kidney Failure
Chronic Inflammation

Treatments

Device: Revaclear 400
Device: MCO-Ci 400

Study type

Interventional

Funder types

Other
Industry

Identifiers

Details and patient eligibility

About

The medium cut-off dialysis membrane has been developed to provide a significantly extended molecular cut-off compared to conventional high-flux membranes. The medium cut-off membrane allows for a high permeability of molecules up to a molecular weight of 45 kDa and has a still limited permeability for albumin (68 kDa).

The main goal of this project is the evaluation of the new, highly porous and selective dialysis membrane (MCO-Ci 400) for the treatment of patients with end-stage renal disease in hemodialysis mode and to study its potential to improve chronic inflammation.

Enrollment

50 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • CKD5 ( GFR < 15ml/min/ 1.73m2)
  • Dialysis treatment for ≥ 3 months
  • Dialysis 3x weekly
  • Vascular access by fistula or CVC
  • Age > 18 and < 99 Years
  • Ability to give written informed consent

Exclusion criteria

  • Missing informed consent form
  • current clinically manifested infection or within the last two weeks
  • current CRP-value > 50mg/L or within the last two weeks
  • Intake of any medication applied for immunosuppressive purposes
  • Pregnancy or lactation
  • Participation in a different interventional study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

50 participants in 2 patient groups

MCO-Ci 400
Experimental group
Description:
MCO-Ci 400 is the investigational medical product applied in hemodialysis mode
Treatment:
Device: MCO-Ci 400
Revaclear 400
Active Comparator group
Description:
the standard high flux dialyzer Revaclear 400 is used as an comparator in hemodialysis mode
Treatment:
Device: Revaclear 400

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems